PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Edaravone→

Edaravone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
89-25-8
PubChem CID
4021
Molecular formula
C10H10N2O
Molecular weight
174.20 g/mol
Drug class
Free-radical scavengerantioxidant neuroprotective small molecule
Mechanism of action
The mechanism by which edaravone produces clinical benefit in amyotrophic lateral sclerosis (ALS) is not fully understood. It scavenges free radicals and may reduce oxidative stress and lipid peroxidation; these effects should not be equated with a proven disease-modifying molecular pathway.
Indications / reported uses
  • Treatment of amyotrophic lateral sclerosis (ALS) in adults under the US product indication; the clinical benefit is described as slowing decline in physical function in the studied population

Sources: US DailyMed — RADICAVA / RADICAVA ORS (edaravone) · US FDA prescribing information · FDA product information

Identification source: PubChem record (CID 4021). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Edaravone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Edaravone Permitted Daily Exposure (PDE) report (the Edaravone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Edaravone Occupational Exposure Limit (OEL) report (the Edaravone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.